Genexine stock lifted upon US FDA okays GX-I7 combination therapy trial

The biotech firm received a go-ahead from the U.S. Food and Drug Administration to conduct a phase 1b clinical trial of a combination treatment of GX-I7(efineptakin alfa) and Novartis’s CAR-T cell therapy Kymriah to treat lymphoma cancer patients. [전체본문 2020-08-26 09:23:00Z]